Research that factor and morbid state, of Congenital Chagas disease in South America

点击翻译按钮获取中文摘要

This study started with epidemiological research of congenital Chags' disease in Bolivia, but now evolve to all around in South America including Independencia area in Ceara state in Northeast Brazil. In Bolivia, we could follow up congenital Chagas' babies who had medicated Benznidazole for three years. After medication by Benznidazole, the pathogen disappeared from the blood of more than 95% of neonate, and swelling of the liver and splenomegaly could not be observed, either. But some were detected pathogen from their blood on the third year, we consider the reason uncompleted medication because the contact with the vector (Triatoma) could deny during their follow-up. It is clear that all of the congenital infected mothers are carriers (32/32), but the necessity of treatment has not been observed, so we need to spread knowledge to people including medical workers.From July 24 to 27 in 2003, Miura spoke about the above-mentioned at the 12th Convention Panamericans' NIKKEI-/Health Section (Aug-2003) in Santa Cruz, Bolivia, and apply for support to JICA Partnership Program. There's no case of congenital Chagas' disease in Northeast Brazil but chronic carriers are still exist and also the vector is still living there, so it is possible that this disease would spread as revival infection. The pathogens (Trypanosoma cruzi) which were isolated from the two countries' were different characteristic, we are evaluating about hereditary difference.